bioAffinity Technologies Inc. logo

bioAffinity Technologies Inc.

BIAF | NASDAQ
Chart Builder DCF Calculator
$8.80
+$1.10 (+14.29%)
Sep 22, 2026, 2:18 PM ET · Market open

Company Profile

As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.

Key Executives

Name Position
Maria Zannes Founder, President, Chief Executive Officer & Director
James Michael Edwards Chief Financial Officer
Xavier T. Reveles Chief Operating Officer
Dallas J. Coleman Vice President of sales
Gordon Downie Chief Medical Officer
Julie Anne Overton Director of Communications
Steven Girgenti Founder & Executive Chairman of the Board
Timothy Zannes Executive Vice President, Secretary & General Counsel
William Bauta Chief Science Officer

Latest SEC Filings

Date Type Title
Sep 03, 2026 8-K Current Report
Sep 03, 2026 S-3/A [Amend] Filing
Sep 01, 2026 8-K Current Report
Aug 27, 2026 S-3 Filing
Aug 20, 2026 8-K Current Report
Aug 18, 2026 8-K Current Report
Aug 14, 2026 8-K Current Report
Aug 07, 2026 10-Q Quarterly Report
Aug 07, 2026 8-K Current Report
Jul 31, 2026 8-K Current Report
View All SEC Filings
bioAffinity Technologies Inc.
bioAffinity Technologies Inc. logo
Country United States
IPO Date Aug 31, 2022
Industry Medical - Diagnostics & Research
Sector Healthcare
Employees 57
CEO Maria Zannes

Contact Details

3300 Nacogdoches Road San Antonio, Texas 78217 United States

Stock Details

Ticker Symbol BIAF
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001712762
CUSIP Number 09076W406
ISIN Number US09076W4069
SIC Code 8731

© 2026 bestshares.com. All rights reserved.